- Vigil Neuroscience Announces $40 Million Strategic Investment from Sanofi
- Vigil Neuroscience to Present in Upcoming June Investor Conferences
- Vigil Neuroscience to Present at The Citizens JMP Life Sciences Conference
- Vigil Neuroscience Reports First Quarter 2024 Financial Results and Provides Business Update
- Vigil Presents Key Findings from ILLUMINATE & IGNITE Studies in ALSP at the 2024 American Academy of Neurology Annual Meeting
- Vigil Neuroscience Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
- Vigil Neuroscience Appoints Petra Kaufmann, M.D., as Chief Medical Officer
- Vigil Announces Upcoming Presentations at 2024 American Academy of Neurology Annual Meeting
- Vigil Neuroscience to Present at Stifel 2024 Virtual CNS Days
- Vigil Announces Oral Presentation on Small Molecule TREM2 Agonist VG-3927 as a Potential Disease-Modifying Therapeutic at AD/PD 2024
More ▼
Key statistics
On Tuesday, Vigil Neuroscience Inc (VIGL:NSQ) closed at 4.01, 62.15% above the 52 week low of 2.47 set on Jun 04, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 4.27 |
---|---|
High | 4.28 |
Low | 3.90 |
Bid | 3.95 |
Offer | 4.09 |
Previous close | 4.37 |
Average volume | 2.17m |
---|---|
Shares outstanding | 37.58m |
Free float | 34.16m |
P/E (TTM) | -- |
Market cap | 164.24m USD |
EPS (TTM) | -2.12 USD |
Data delayed at least 15 minutes, as of Jul 02 2024 21:00 BST.
More ▼